Clinical Trials Browser

Phase 2 × Active not recruiting × Breast Neoplasms × Clear all

NCT02738866 2026-06-05

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

Phase 2 Active not recruiting

Breast Neoplasms

NCT00609791 2026-06-04

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer

Phase 2 Active not recruiting

40 enrolled 16 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT03768492 2026-06-04

ReDCoAT

Phase 2 Active not recruiting

Breast Neoplasms

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02927912 2026-06-03

Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction

Phase 2 Active not recruiting

108 enrolled 8 charts

Breast Neoplasms

NCT02311933 2026-05-29

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Phase 2 Active not recruiting

81 enrolled 9 charts

Breast Neoplasms

NCT05203445 2026-05-29

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

Phase 2 Active not recruiting

6 enrolled 9 charts

Breast Neoplasms

NCT02883062 2026-05-28

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04568616 2026-05-28

NAOMI

Phase 2 Active not recruiting

Breast Neoplasms

NCT02568267 2026-05-27

STARTRK-2

Phase 2 Active not recruiting

534 enrolled 1 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT00585507 2026-05-22

Efficacy and Safety of 500mg of Fulvestrant

Phase 2 Active not recruiting

Breast Neoplasms

NCT02849496 2026-05-22

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT04007770 2026-05-22

Acupuncture Pilot Study for Cancer-related Cognitive Function

Phase 2 Active not recruiting

BreastGastrointestinalGenitourinary

Breast Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT05392608 2026-05-22

SEQUEL-Breast

Phase 2 Active not recruiting

Breast Neoplasms, Genetic Diseases, Inborn

NCT05675579 2026-05-20

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Phase 2 Active not recruiting

Breast Neoplasms

NCT03587740 2026-05-18

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

Phase 2 Active not recruiting

111 enrolled 20 charts

Breast Neoplasms

NCT06618014 2026-05-15

NeoTOP

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05296746 2026-05-14

RIBOLARIS

Phase 2 Active not recruiting

Breast Neoplasms

NCT04584255 2026-05-13

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT05812924 2026-05-13

A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause

Phase 2 Active not recruiting

Breast Neoplasms

NCT03609047 2026-05-12

Appalaches

Phase 2 Active not recruiting

Breast Neoplasms

NCT03941730 2026-05-12

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Phase 2 Active not recruiting

8 enrolled 9 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01621659 2026-05-11

TITAN

Phase 2 Active not recruiting

Breast Neoplasms, Motor Activity

NCT06271837 2026-05-11

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Phase 2 Active not recruiting

Breast Neoplasms

NCT06048718 2026-05-08

TUXEDO-4

Phase 2 Active not recruiting

Brain Neoplasms, Breast Neoplasms

NCT05596409 2026-05-07

ELCIN

Phase 2 Active not recruiting

Breast Neoplasms

NCT04553133 2026-05-06

PF-07104091 as a Single Agent and in Combination Therapy

Phase 2 Active not recruiting

BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT05591547 2026-05-06

APBI RISE

Phase 2 Active not recruiting

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT02942355 2026-05-05

Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT04316117 2026-05-05

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Phase 2 Active not recruiting

Breast Neoplasms

NCT01245712 2026-05-01

Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer

Phase 2 Active not recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT02498613 2026-05-01

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Phase 2 Active not recruiting

122 enrolled 16 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04733118 2026-04-29

PHERGAIN-2

Phase 2 Active not recruiting

Breast Neoplasms

NCT06172127 2026-04-29

DEMETHER

Phase 2 Active not recruiting

Breast Neoplasms

NCT03789110 2026-04-28

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Phase 2 Active not recruiting

30 enrolled 15 charts

Breast Neoplasms

NCT05645380 2026-04-28

NeoTRACT

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04373031 2026-04-24

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

Phase 2 Active not recruiting

12 enrolled 11 charts

Breast Neoplasms

NCT04837820 2026-04-22

The Effect of Acupuncture on Cancer-Related Cognitive Difficulties

Phase 2 Active not recruiting

Breast Neoplasms

NCT02957968 2026-04-21

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Phase 2 Active not recruiting

46 enrolled 21 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03820141 2026-04-20

DTP

Phase 2 Active not recruiting

51 enrolled 12 charts

Breast Neoplasms

NCT02326974 2026-04-17

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Phase 2 Active not recruiting

164 enrolled 19 charts

Breast Neoplasms

NCT03971409 2026-04-17

InCITe

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02754752 2026-04-15

Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment

Phase 2 Active not recruiting

Breast Neoplasms

NCT02876107 2026-04-15

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms, Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06840483 2026-04-15

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT04920708 2026-04-14

FAIM

Phase 2 Active not recruiting

Breast Neoplasms

NCT03650894 2026-04-13

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Phase 2 Active not recruiting

Breast Neoplasms

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Phase 2 Active not recruiting

329 enrolled 23 charts

BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT06702618 2026-04-09

Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT06604858 2026-04-07

TELESCOPE

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms